How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these important clinical questions in a contemporary cohort of patients.
In the first part, Prof Fontana provides a deep dive into the latest findings from the ATTRibute-CM study, focusing on outpatient worsening heart failure in ATTR-CM. She explores disease mechanisms and unmet treatment needs, study design, key outcomes, clinical conclusions and their implications.
In the second part, Prof Fontana is joined by Dr Esther González López (Hospital Puerta de Hierro Majadahonda, Madrid, ES) for a peer-to-peer discussion that places the ATTRibute-CM findings into real-world clinical context. This expert-led conversation explores the following:
- What the data adds to the current landscape
- Implications for clinical practice
- Insights from other key data presented at HFA
- Remaining questions and unmet needs in ATTR-CM
- Key takeaways for clinical practice
This session provides valuable perspective, helping translate emerging evidence into meaningful clinical insight. Whether you’re looking for a quick update or a deeper clinical analysis, this series is designed to support informed decision-making in ATTR-CM.
Key Learning Objectives
- Describe outpatient worsening HF and its significance as a marker of disease progression in ATTR-CM
- Summarise the relationship between worsening HF and clinical outcomes in ATTR-CM in the ATTRibute-CM trial
- Recall how soon acoramidis achieved significant reduction in worsening HF events in the ATTRibute-CM trial
Target Audience
- Heart Failure Specialists
- Cardiologists
- Cardiovascular Specialists
More from this programme
Part 1
Data Deep-Dive: ATTRibute-CM Outpatient Worsening HF Outcomes
Prof Fontana provides a deep dive into the ATTRibute-CM late-breaking data, focusing on outpatient worsening heart failure in ATTR-CM. She explores disease mechanisms and unmet treatment needs, study design, key outcomes, clinical conclusions and their implications.
Part 2
In Context: A Peer-To-Peer Discussion on the ATTRibute-CM Data
Prof Fontana and Dr González López apply the ATTRibute-CM findings into real-world clinical context. This expert-led conversation explores what the data adds to the current landscape, implications for clinical practice and insights from other key data presented at HFA.
Faculty Biographies
Esther González López
Dr Esther Gonzalez-Lopez trained in Cardiology at Hospital Puerta de Hierro Majadahonda (HUPHM) in Madrid, where she completed her doctoral thesis on imaging techniques in transthyretin cardiac amyloidosis. Her work, including the acclaimed paper "Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction" (Eur Heart J. 2015), won the Dr. Cardeñosa Research Prize in 2015. She has also conducted research at CNIC in Madrid, Brigham and Women's Hospital in Boston, and worked as a Consultant Cardiologist at the National Amyloidosis Centre in London. Currently, she is at HUPHM, supported by a Juan Rodés grant, focusing on cardiac imaging and inherited cardiac diseases, especially transthyretin cardiac amyloidosis.
Marianna Fontana
Professor of Cardiology and Honorary Consultant Cardiologist
Prof Marianna Fontana is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, London, UK.
Her main clinical and research interests include the delivery of efficient and effective care for patients with amyloidosis, with a particular focus on new technologies.
Comments